Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages
This cohort study shows that access to alternatives may have mitigated gaps in treatment during the 2018 to 2019 ARB recalls and drug shortages. Potential disparate impacts among certain subgroups highlight the need for policies to mitigate financial and other systematic access barriers to receiving health care during drug shortages.
Authors
- Eric T. Roberts (ORCID: https://orcid.org/0000-0002-7439-0799)
- Katie J. Suda
- Chester B. Good (ORCID: https://orcid.org/0000-0003-4388-4558)
- Mina Tadrous (ORCID: https://orcid.org/0000-0003-1911-6129)
- Julie M. Donohue
- Lindsay M. Sabik (ORCID: https://orcid.org/0000-0002-0613-4929)
- Joshua W. Devine (ORCID: https://orcid.org/0009-0004-1508-3846)
- Katherine Callaway Kim (ORCID: https://orcid.org/0000-0002-2924-6165)
Institutions
- University of Pittsburgh (US)
- University of Toronto (CA)
- Women's College Hospital (CA)
- Men's Health Forum (GB)
- VA Pittsburgh Healthcare System (US)
- UPMC Center for High Value Health Care (US)
- University of Pennsylvania (US)
- Des Moines University (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1001/jamahealthforum.2025.4078
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Veterans Affairs
- University of Southern California
- Arnold Ventures
- Soochow University
- National Institutes of Health
- Agency for Healthcare Research and Quality
- Health Canada